date,title,source
Oct-31-18,Aytu BioScience to Report Fiscal First Quarter 2019 Results and Business Update,ACCESSWIRE
Nov-05-18,"Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra(R) XR",ACCESSWIRE
Nov-07-18,Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra(R) XR to Portfolio,ACCESSWIRE
Nov-07-18,Biotech Stocks and the Midterm Elections,ACCESSWIRE
Nov-13-18,"Aytu BioScience to Report Interim Results from Natesto(R) Spermatogenesis Study on Thursday, November 15, 2018",ACCESSWIRE
Nov-15-18,Aytu BioScience Announces Positive Interim Results from Natesto(R) Spermatogenesis Study,ACCESSWIRE
Nov-16-18,"Investor Expectations to Drive Momentum within ANGI Homeservices, Aytu Bioscience, IRIDEX, Cellular Biomedicine Group, CounterPath, and EXFO  Discovering Underlying Factors of Influence",GlobeNewswire
Nov-30-18,Aytu BioScience Announces Closing of $5M Investment from Armistice Capital,ACCESSWIRE
Dec-03-18,"Aytu BioScience Announces Appointment of Two New Directors, Steven Boyd and Ketan Mehta",ACCESSWIRE
